
## David Balayssac

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5327855/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Relation between auditory difficulties and bortezomib-induced peripheral neuropathy in multiple myeloma: a single-center cross-sectional study. European Archives of Oto-Rhino-Laryngology, 2022, 279, 2197-2201.	0.8	2
2	Analgesic and preventive effects of donepezil in animal models of chemotherapy-induced peripheral neuropathy: Involvement of spinal muscarinic acetylcholine M2 receptors. Biomedicine and Pharmacotherapy, 2022, 149, 112915.	2.5	5
3	The Class I HDAC Inhibitor, MS-275, Prevents Oxaliplatin-Induced Chronic Neuropathy and Potentiates Its Antiproliferative Activity in Mice. International Journal of Molecular Sciences, 2022, 23, 98.	1.8	8
4	Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial. BMC Cancer, 2022, 22, .	1.1	2
5	Clinical and Organizational Impact of the AIRSEAL <sup>®</sup> Insufflation System During Laparoscopic Surgery: A Systematic Review. World Journal of Surgery, 2021, 45, 705-718.	0.8	12
6	The Safety of Medications used to Treat Peripheral Neuropathic Pain, Part 2 (Opioids, Cannabinoids and) Tj ETQqC on Drug Safety, 2021, 20, 51-68.	0 0 rgBT 1.0	/Overlock 1 4
7	Prevention, diagnosis and management of chemotherapy-induced peripheral neuropathy: a cross-sectional study of French oncologists' professional practices. Supportive Care in Cancer, 2021, 29, 4033-4043.	1.0	12
8	Epigenetics Involvement in Oxaliplatin-Induced Potassium Channel Transcriptional Downregulation and Hypersensitivity. Molecular Neurobiology, 2021, 58, 3575-3587.	1.9	8
9	Prevalence of Chemotherapy-Induced Peripheral Neuropathy in Multiple Myeloma Patients and its Impact on Quality of Life: A Single Center Cross-Sectional Study. Frontiers in Pharmacology, 2021, 12, 637593.	1.6	26
10	Ramipril Alleviates Oxaliplatin-Induced Acute Pain Syndrome in Mice. Frontiers in Pharmacology, 2021, 12, 712442.	1.6	9
11	A new clinically-relevant rat model of letrozole-induced chronic nociceptive disorders. Toxicology and Applied Pharmacology, 2021, 425, 115600.	1.3	1
12	Perception of Pharmacy Students Toward Opioid-Related Disorders and Roles of Community Pharmacists: A French Nationwide Cross-Sectional Study. Substance Abuse, 2021, 42, 706-715.	1.1	2
13	Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients' Profiles With Oxaliplatin-Induced Peripheral Neuropathy. Frontiers in Pharmacology, 2021, 12, 744085.	1.6	3
14	Burnout in French General Practitioners: A Nationwide Prospective Study. International Journal of Environmental Research and Public Health, 2021, 18, 12044.	1.2	15
15	Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study. Journal of Clinical Medicine, 2020, 9, 2400.	1.0	42
16	The safety of medications used to treat peripheral neuropathic pain, part 1 (antidepressants and) Tj ETQq0 0 0 rg on Drug Safety, 2020, 19, 707-733.	3T /Overlo 1.0	ck 10 Tf 50 10
17	Assessment of the advantage of the serum S100B protein biomonitoring in the management of paediatric mild traumatic brain injury—PROS100B: protocol of a multicentre unblinded stepped wedge cluster randomised trial. BMJ Open, 2019, 9, e027365.	0.8	11
18	Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the	0.8	15

 18
 RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the
 0.8

 UNICANCER-AFSOS Supportive Care intergroup. BMJ Open, 2019, 9, e027770.
 0.8

DAVID BALAYSSAC

#	Article	IF	CITATIONS
19	Cannabis users: Screen systematically, treat individually. A descriptive study of participants in a randomized trial in primary care. PLoS ONE, 2019, 14, e0224867.	1.1	ο
20	Use of Psychotropic Medications and Illegal Drugs, and Related Consequences Among French Pharmacy Students – SCEP Study: A Nationwide Cross-Sectional Study. Frontiers in Pharmacology, 2018, 9, 725.	1.6	14
21	Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin. Neuropharmacology, 2018, 140, 43-61.	2.0	56
22	Warmed and humidified carbon dioxide for abdominal laparoscopic surgery: meta-analysis of the current literature. Surgical Endoscopy and Other Interventional Techniques, 2017, 31, 1-12.	1.3	39
23	Clinical assessment of new antineuropathic strategies for chemotherapy-induced peripheral neuropathy: pain should not be the principal endpoint. Pain, 2017, 158, 180-182.	2.0	11
24	Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review. Frontiers in Pharmacology, 2017, 8, 86.	1.6	219
25	Work-related stress, associated comorbidities and stress causes in French community pharmacies: a nationwide cross-sectional study. PeerJ, 2017, 5, e3973.	0.9	17
26	Burnout, associated comorbidities and coping strategies in French community pharmacies—BOP study: A nationwide cross-sectional study. PLoS ONE, 2017, 12, e0182956.	1.1	46
27	What are the Most Important Decision-Making Criteria For Innovative Health Technology Integration? A National Survey from French Hospitals Decision-Makers. Value in Health, 2016, 19, A489.	0.1	2
28	Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study. PLoS ONE, 2016, 11, e0148739.	1.1	11
29	Assessment of Mechanical Allodynia in Rats Using the Electronic Von Frey Test. Bio-protocol, 2016, 6, .	0.2	14
30	Response to "Use of Domperidone to Increase Breast Milk Supply: Further Consideration of the Benefit-Risk Ratio Is Required― Journal of Human Lactation, 2015, 31, 316-317.	0.8	0
31	Cholinergic Neurotransmission in the Posterior Insular Cortex Is Altered in Preclinical Models of Neuropathic Pain: Key Role of Muscarinic M2 Receptors in Donepezil-Induced Antinociception. Journal of Neuroscience, 2015, 35, 16418-16430.	1.7	36
32	Therapeutic management of complex anal fistulas by installing a nitinol closure clip: study protocol of a multicentric randomised controlled trial—FISCLOSE: TableÂ1. BMJ Open, 2015, 5, e009884.	0.8	13
33	Use of Domperidone as a Galactagogue Drug. Journal of Human Lactation, 2015, 31, 57-63.	0.8	38
34	Minimizing chemotherapy-induced peripheral neuropathy: preclinical and clinical development of new perspectives. Expert Opinion on Drug Safety, 2015, 14, 1269-1282.	1.0	29
35	Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced dietNEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial. BMJ Open, 2015, 5, e007479-e007479.	0.8	18
36	Assessment of thermal sensitivity in rats using the thermal place preference test. Behavioural Pharmacology, 2014, 25, 99-111.	0.8	30

DAVID BALAYSSAC

#	Article	IF	CITATIONS
37	Emerging Trends in Understanding Chemotherapy-Induced Peripheral Neuropathy. Current Pain and Headache Reports, 2013, 17, 364.	1.3	45
38	Mécanismes épigénétiques impliqués dans la douleur chronique. Douleur Et Analgesie, 2013, 26, 234-240.	0.2	0
39	Use of Permacol in Parietal and General Surgery. Surgical Innovation, 2013, 20, 176-182.	0.4	7
40	A Polyamine-Deficient Diet Prevents Oxaliplatin-Induced Acute Cold and Mechanical Hypersensitivity in Rats. PLoS ONE, 2013, 8, e77828.	1.1	30
41	Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opinion on Drug Safety, 2011, 10, 407-417.	1.0	101
42	Neurotoxicité périphérique des traitements oncologiques: aspects précliniques et cliniques. , 2010, , 223-234.		0
43	Animal Models of Chemotherapy-Evoked Painful Peripheral Neuropathies. Neurotherapeutics, 2009, 6, 620-629.	2.1	94
44	Increase in morphine antinociceptive activity by a P-glycoprotein inhibitor in cisplatin-induced neuropathy. Neuroscience Letters, 2009, 465, 108-112.	1.0	13
45	Enquête sur la préparation et le contrÃ1e des mélanges nutritifs parentéraux dans les pharmacies Ã usage intérieur des centres hospitaliers universitaires. Nutrition Clinique Et Metabolisme, 2008, 22, 27-32.	0.2	6
46	Association of Cannabis Smoking and Periodontal Disease. JAMA - Journal of the American Medical Association, 2008, 299, 2273.	3.8	2
47	Vincristine-Induced Neuropathy in the Rat Is Not Modified by Drug-Drug Interactions with the P-Clycoprotein Inhibitor Verapamil. Chemotherapy, 2008, 54, 336-342.	0.8	6
48	Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain, 2007, 128, 225-234.	2.0	131
49	Behavioral and immunohistological assessment of painful neuropathy induced by a single oxaliplatin injection in the rat. Toxicology, 2007, 234, 176-184.	2.0	93
50	Involvement of the multidrug resistance transporters in cisplatin-induced neuropathy in rats. Comparison with the chronic constriction injury model and monoarthritic rats. European Journal of Pharmacology, 2006, 544, 49-57.	1.7	8
51	Patterns of P-glycoprotein activity in the nervous system during vincristine-induced neuropathy in rats. Journal of the Peripheral Nervous System, 2005, 10, 301-310.	1.4	32
52	Does inhibition of P-glycoprotein lead to drug–drug interactions?. Toxicology Letters, 2005, 156, 319-329.	0.4	153
53	Assessment of nociception in acrylamide-induced neuropathy in rats. Pain, 2005, 119, 104-112.	2.0	22

Letter to editor. Nuclear Medicine and Biology, 2003, 30, 455.

0.3 1

#	Article	IF	CITATIONS
55	Absence of painful neuropathy after chronic oral fluoride intake in Sprague–Dawley and Lou/C rats. Neuroscience Letters, 2002, 327, 169-172.	1.0	5